Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 74, Issue 2, 2014, Pages 132-142

  Mikulová, Veronika ^a   Čabiňaková, Michaela ^b   Janatková, Ivana ^a   Mestek, Otto ^c   Zima, Tomáš ^a   Tesařová, Petra ^b  

^a Laboratory of Clinical Immunology and Allergology Institute of Medical Biochemistry and Laboratory Diagnostics   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

Author keywords

Breast cancer; Circulating tumor cells; Gene expression monitoring; Genetic; Heterogeneity; Treatment efficacy

Indexed keywords

ACTIN; ANTINEOPLASTIC AGENT; CATHEPSIN D; COMPLEMENTARY DNA; CYTOKERATIN 19; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; MUCIN 1; SIALYLTRANSFERASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CIRCULATING TUMOR CELL; DISEASE COURSE; EARLY CANCER; FOLLOW UP; GENE EXPRESSION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CHEMOTHERAPY, ADJUVANT; DRUG MONITORING; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMANS; MIDDLE AGED; MUCIN-1; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RNA, MESSENGER; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84896337530     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2013.864784     Document Type: Article

References (30)

1. Dusek L, Muzik J, Kubasek M, Koptikova J, Zaloudik J, Vyzula R. Epidemiology of malignant tumors in Czech Republic. [online]. Masaryk's University [2005], [cit. 2012-10-16]. Available from www: http://www.svod.cz. Verze 7.0 [2007], ISSN 1802-8861.
2. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmuller G, Klein CA. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13: 58-68. (Pubitemid 350309740)
3. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008; 8: 329-40. (Pubitemid 351596394)
4. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer microme-tastases. Nat Rev Clin Oncol 2009; 6: 339-51.
5. Ross JS, Slodkowska EA. Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol 2009; 132: 237-45.
6. Alunni-Fabbroni M, Sandri MT. Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods 2010; 50: 289-97.
7. Giuliano M, Giordano A, Jackson S, Hess KR, De GU, Mego M, Handy BC, Ueno NT, Alvarez RH, De LM, De PS, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 2011; 13: R67.
8. Gradilone A, Naso G, Raimondi C, Cortesi E, Gandini O, Vincenzi B, Saltarelli R, Chiapparino E, Spremberg F, Cristofanilli M, Frati L, Agliano AM, Gazzaniga P. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann Oncol 2011; 22: 86-92.
9. Hauch S, Zimmermann S, Lankiewicz S, Zieglschmid V, Bocher O, Albert WH. The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients. Anticancer Res 2007; 27: 1337-41. (Pubitemid 46807280)
10. Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, Kanellou P, Kotsakis A, Politaki E, Kalbakis K, Kalykaki A, Vamvakas L, Georgoulias V, Mavroudis D. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 2007; 18: 851-8. (Pubitemid 47054081)
11. Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C, Stathopoulos E, Georgoulias V, Mavroudis D. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. Breast Cancer Res Treat 2009; 117: 525-34.
12. Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, Marty M, Pierga JY. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010; 21: 729-33.
13. Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S, Lucci A. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 2010; 116: 3330-7.
14. Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16: 2634-45.
15. Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, Kimmig R, Kasimir-Bauer S. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009; 11: R59.
16. Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA, Cristofanilli M. Comparison of assay methods for detection of circulating tumor cells (CTCs) in metastatic breast cancer (MBC): AdnaGen AdnaTest BreastCancer Select/Detect versus Veri-dex CellSearch system. Int J Cancer 2011; 130: 1590-1597.
17. Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prove A, Maes H, Huget P, van Dam P, Vermeulen PB, Dirix LY. Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 2010; 102: 276-84.
18. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005; 93: 552-6. (Pubitemid 43079998)
19. Pourquier P, Pommier Y. Topoisomerase I-mediated DNA damage. Adv Cancer Res 2001; 80: 189-216.
20. Pourquier P, Pommier Y. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance]. Bull Cancer 1998; Spec No: 5-10.
21. Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treat Rev 2009; 35: 662-7.
22. Liaudet-Coopman E, Beaujouin M, Derocq D, Garcia M, Glondu-Lassis M, Laurent-Matha V, Prebois C, Rochefort H, Vignon F. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett 2006; 237: 167-79. (Pubitemid 43777078)
23. Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K, Agelaki S, Kalykaki A, Georgoulias V, Mavroudis D. Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Res 2011; 13: R60.
24. Tsuchida A, Okajima T, Furukawa K, Ando T, Ishida H, Yoshida A, Nakamura Y, Kannagi R, Kiso M, Furukawa K. Synthesis of disialyl Lewis a (Le(a)) structure in colon cancer cell lines by a sialyltransferase, ST6GalNAc VI, responsible for the synthesis of alpha-series gangliosides. J Biol Chem 2003; 278: 22787-94. (Pubitemid 36830340)
25. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massague J. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459: 1005-9.
26. Biggers B, Knox S, Grant M, Kuhn J, Nemunatitis J, Fisher T, Lamont J. Circulating tumor cells in patients undergoing surgery for primary breast cancer: preliminary results of a pilot study. Ann Surg Oncol 2009; 16: 969-71.
27. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer microme-tastases. Nat Rev Clin Oncol 2009; 6: 339-51.
28. Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, de Cremoux P, Salmon R, Vincent-Salomon A, Marty M. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008; 14: 7004-10.
29. Rack BK, Schindlbeck C, Andergassen U, Schneeweiss A, Zwingers T, Lichtenegger W, Beckmann M, Sommer HL, Pantel K, Janni W. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: the SUCCESS trial. J Clin Oncol 2010; 28:(15 suppl.): 1003.
30. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012; 9: e1001216.